226 related articles for article (PubMed ID: 20045346)
1. Low incidence of malignancy in heart-transplant recipients in Taiwan: an update and comparison with kidney-transplant recipients.
Hsu RB; Chang CI; Tsai MK; Lee PH; Chou NK; Chi NH; Wang SS; Chu SH
Eur J Cardiothorac Surg; 2010 May; 37(5):1117-21. PubMed ID: 20045346
[TBL] [Abstract][Full Text] [Related]
2. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
[TBL] [Abstract][Full Text] [Related]
3. Bloodstream infection in heart transplant recipients: 12-year experience at a university hospital in Taiwan.
Hsu RB; Chang CI; Fang CT; Chang SC; Wang SS; Chu SH
Eur J Cardiothorac Surg; 2011 Dec; 40(6):1362-7. PubMed ID: 21459606
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
[TBL] [Abstract][Full Text] [Related]
5. Low incidence of malignancy after transplantation in Chinese heart allograft recipients.
Hsu RB; Chen RJ; Chou NK; Ko WJ; Wang SS; Chu SH
Transpl Int; 2005 Mar; 18(3):283-8. PubMed ID: 15730487
[TBL] [Abstract][Full Text] [Related]
6. Chronologically different incidences of post-transplant malignancies in renal transplant recipients: single center experience.
Ju MK; Joo DJ; Kim SJ; Huh KH; Kim MS; Jeon KO; Kim HJ; Kim SI; Kim YS
Transpl Int; 2009 Jun; 22(6):644-53. PubMed ID: 19220824
[TBL] [Abstract][Full Text] [Related]
7. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients.
Libertiny G; Watson CJ; Gray DW; Welsh KI; Morris PJ
Br J Surg; 2001 Oct; 88(10):1330-4. PubMed ID: 11578286
[TBL] [Abstract][Full Text] [Related]
8. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
[TBL] [Abstract][Full Text] [Related]
9. Trends in invasive disease due to Candida species following heart and lung transplantation.
Schaenman JM; Rosso F; Austin JM; Baron EJ; Gamberg P; Miller J; Oyer PE; Robbins RC; Montoya JG
Transpl Infect Dis; 2009 Apr; 11(2):112-21. PubMed ID: 19254327
[TBL] [Abstract][Full Text] [Related]
10. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
Walker RC; Paya CV; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; Daly RC; McGregor CG
J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838
[TBL] [Abstract][Full Text] [Related]
11. High incidence of urinary tract malignancy among patients with haematuria following kidney transplantation in Taiwan.
Tai HC; Lai MK; Wang SM; Chueh SC; Yu HJ
Transpl Int; 2009 Apr; 22(4):403-7. PubMed ID: 19040485
[TBL] [Abstract][Full Text] [Related]
12. [Post-transplant lymphoproliferative disorders in renal transplantation: two decades of experience].
Franco A; Jiménez L; Sillero C; Trigueros M; González D; Alcaraz E; Olivares J
Nefrologia; 2010; 30(6):669-75. PubMed ID: 21113217
[TBL] [Abstract][Full Text] [Related]
13. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?
Burra P; Buda A; Livi U; Rigotti P; Zanus G; Calabrese F; Caforio A; Menin C; Canova D; Farinati F; Luciana Aversa SM
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1065-70. PubMed ID: 16957512
[TBL] [Abstract][Full Text] [Related]
14. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.
Schubert S; Renner C; Hammer M; Abdul-Khaliq H; Lehmkuhl HB; Berger F; Hetzer R; Reinke P
J Heart Lung Transplant; 2008 Jan; 27(1):100-5. PubMed ID: 18187094
[TBL] [Abstract][Full Text] [Related]
15. [Lymphoproliferative disease and cancer in the transplant patient].
Herreros J; Flórez S; Echevarría JR; Fernández AL; Pardo Mindán FJ
Rev Esp Cardiol; 1995; 48 Suppl 7():129-34. PubMed ID: 8775827
[TBL] [Abstract][Full Text] [Related]
16. Malignancy in pediatric transplant recipients.
Buell JF; Gross TG; Thomas MJ; Neff G; Muthiah C; Alloway R; Ryckman FC; Tiao GM; Woodle ES
Semin Pediatr Surg; 2006 Aug; 15(3):179-87. PubMed ID: 16818139
[TBL] [Abstract][Full Text] [Related]
17. Lymphoproliferative disorders and hematologic malignancies following organ transplantation.
Ferry JA; Jacobson JO; Conti D; Delmonico F; Harris NL
Mod Pathol; 1989 Nov; 2(6):583-92. PubMed ID: 2587566
[TBL] [Abstract][Full Text] [Related]
18. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
[TBL] [Abstract][Full Text] [Related]
19. Malignancies in organ transplant recipients.
Hoshida Y; Aozasa K
Pathol Int; 2004 Sep; 54(9):649-58. PubMed ID: 15363032
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma.
Opelz G; Daniel V; Naujokat C; Döhler B
Transplantation; 2009 Oct; 88(8):962-7. PubMed ID: 19855238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
